235 related articles for article (PubMed ID: 26204569)
1. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA
Int J Cardiol; 2015 Nov; 199():204-12. PubMed ID: 26204569
[TBL] [Abstract][Full Text] [Related]
2. Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit.
Wu BJ; Shrestha S; Ong KL; Johns D; Hou L; Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):628-36. PubMed ID: 25633313
[TBL] [Abstract][Full Text] [Related]
3. Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition.
Wu BJ; Li Y; Ong KL; Sun Y; Shrestha S; Hou L; Johns D; Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2333-2341. PubMed ID: 29025709
[TBL] [Abstract][Full Text] [Related]
4. The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits.
Wu BJ; Li Y; Ong KL; Sun Y; Johns D; Barter PJ; Rye KA
Sci Rep; 2019 Nov; 9(1):16183. PubMed ID: 31700015
[TBL] [Abstract][Full Text] [Related]
5. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein.
Han S; Levoci L; Fischer P; Wang SP; Gagen K; Chen Y; Xie D; Fisher T; Ehrhardt AG; Peier AM; Johns DG
Biochim Biophys Acta; 2013 Apr; 1831(4):825-33. PubMed ID: 23269286
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis.
Trinder M; Wang Y; Madsen CM; Ponomarev T; Bohunek L; Daisely BA; Julia Kong H; Blauw LL; Nordestgaard BG; Tybjærg-Hansen A; Wurfel MM; Russell JA; Walley KR; Rensen PCN; Boyd JH; Brunham LR
Circulation; 2021 Mar; 143(9):921-934. PubMed ID: 33228395
[TBL] [Abstract][Full Text] [Related]
8. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
[TBL] [Abstract][Full Text] [Related]
9. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
[TBL] [Abstract][Full Text] [Related]
11. Anacetrapib: hope for CETP inhibitors?
Gurfinkel R; Joy TR
Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
[TBL] [Abstract][Full Text] [Related]
12. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
13. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
14. Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits.
Zhang J; Niimi M; Yang D; Liang J; Xu J; Kimura T; Mathew AV; Guo Y; Fan Y; Zhu T; Song J; Ackermann R; Koike Y; Schwendeman A; Lai L; Pennathur S; Garcia-Barrio M; Fan J; Chen YE
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1068-1075. PubMed ID: 28428219
[TBL] [Abstract][Full Text] [Related]
15. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
16. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
17. Anacetrapib: a potential new therapy for dyslipidemia.
Robinson LB; Frishman WH
Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931
[TBL] [Abstract][Full Text] [Related]
18. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Masson D
Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
[TBL] [Abstract][Full Text] [Related]
19. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques.
Roddy TP; McLaren DG; Chen Y; Xie D; Dunn K; Kulick A; Szeto D; Forrest G; Albanese K; Donnelly M; Gai C; Gewain A; Lederman H; Jensen KK; Ai X; Vachal P; Akinsanya KO; Cleary MA; Previs SF; Dansky HM; Johns DG
Eur J Pharmacol; 2014 Oct; 740():410-6. PubMed ID: 24769414
[TBL] [Abstract][Full Text] [Related]
20. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):543-9. PubMed ID: 24737712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
